Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Esperion Therapeutics, Inc. (ESPR : NSDQ)
 
 • Company Description   
Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan.

Number of Employees: 479

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.25 Daily Weekly Monthly
20 Day Moving Average: 1,699,498 shares
Shares Outstanding: 29.08 (millions)
Market Capitalization: $152.65 (millions)
Beta: 0.91
52 Week High: $39.50
52 Week Low: $4.96
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -50.19% -48.64%
12 Week -56.25% -56.69%
Year To Date -79.81% -71.69%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3891 RANCHERO DRIVE SUITE 150
-
ANN ARBOR,MI 48108
USA
ph: 734-887-3903
fax: -
ir@esperion.com http://www.esperion.com
 
 • General Corporate Information   
Officers
Tim M. Mayleben - President; Chief Executive Officer and Director
Richard B. Bartram - Chief Financial Officer
Jeffrey Berkowitz - Director
Alan Fuhrman - Director
Antonio M. Gotto - Director

Peer Information
Esperion Therapeutics, Inc. (GSAC)
Esperion Therapeutics, Inc. (CASI)
Esperion Therapeutics, Inc. (ALCD.)
Esperion Therapeutics, Inc. (OMNN)
Esperion Therapeutics, Inc. (CGPI.)
Esperion Therapeutics, Inc. (ISR)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 29664W105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 02/22/22
Share - Related Items
Shares Outstanding: 29.08
Most Recent Split Date: (:1)
Beta: 0.91
Market Capitalization: $152.65 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-2.74 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-10.56 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/22/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 2.10
EPS Growth
vs. Year Ago Period: 14.66%
vs. Previous Quarter: -56.89%
Sales Growth
vs. Year Ago Period: 275.92%
vs. Previous Quarter: -64.56%
ROE
09/30/21 - -
06/30/21 - -
03/31/21 - -
ROA
09/30/21 - -108.46
06/30/21 - -111.58
03/31/21 - -51.51
Current Ratio
09/30/21 - 2.17
06/30/21 - 3.33
03/31/21 - 2.78
Quick Ratio
09/30/21 - 1.74
06/30/21 - 3.04
03/31/21 - 2.58
Operating Margin
09/30/21 - -424.39
06/30/21 - -522.50
03/31/21 - -66.86
Net Margin
09/30/21 - -424.39
06/30/21 - -522.50
03/31/21 - -66.86
Pre-Tax Margin
09/30/21 - -424.39
06/30/21 - -522.50
03/31/21 - -66.86
Book Value
09/30/21 - -12.47
06/30/21 - -10.77
03/31/21 - -9.57
Inventory Turnover
09/30/21 - 0.46
06/30/21 - 0.32
03/31/21 - 0.31
Debt-to-Equity
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Capital
09/30/21 - -
06/30/21 - -
03/31/21 - -
 

Powered by Zacks Investment Research ©